EP3609329A4 - Compositions, produits pharmaceutiques conditionnés, et méthodes d'utilisation de posaconazole pour la sensibilisation de tumeurs résistantes - Google Patents

Compositions, produits pharmaceutiques conditionnés, et méthodes d'utilisation de posaconazole pour la sensibilisation de tumeurs résistantes Download PDF

Info

Publication number
EP3609329A4
EP3609329A4 EP18783809.9A EP18783809A EP3609329A4 EP 3609329 A4 EP3609329 A4 EP 3609329A4 EP 18783809 A EP18783809 A EP 18783809A EP 3609329 A4 EP3609329 A4 EP 3609329A4
Authority
EP
European Patent Office
Prior art keywords
posaconazole
sensitization
compositions
methods
resistant tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18783809.9A
Other languages
German (de)
English (en)
Other versions
EP3609329A1 (fr
Inventor
Vikash J. BHAGWANDIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP3609329A1 publication Critical patent/EP3609329A1/fr
Publication of EP3609329A4 publication Critical patent/EP3609329A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP18783809.9A 2017-04-12 2018-04-12 Compositions, produits pharmaceutiques conditionnés, et méthodes d'utilisation de posaconazole pour la sensibilisation de tumeurs résistantes Withdrawn EP3609329A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762484852P 2017-04-12 2017-04-12
PCT/US2018/027371 WO2018191541A1 (fr) 2017-04-12 2018-04-12 Compositions, produits pharmaceutiques conditionnés, et méthodes d'utilisation de posaconazole pour la sensibilisation de tumeurs résistantes

Publications (2)

Publication Number Publication Date
EP3609329A1 EP3609329A1 (fr) 2020-02-19
EP3609329A4 true EP3609329A4 (fr) 2021-03-17

Family

ID=63793667

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18783809.9A Withdrawn EP3609329A4 (fr) 2017-04-12 2018-04-12 Compositions, produits pharmaceutiques conditionnés, et méthodes d'utilisation de posaconazole pour la sensibilisation de tumeurs résistantes

Country Status (6)

Country Link
EP (1) EP3609329A4 (fr)
KR (1) KR20200059188A (fr)
CN (1) CN111093373A (fr)
AU (1) AU2018253189A1 (fr)
CA (1) CA3063115A1 (fr)
WO (1) WO2018191541A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013037043A1 (fr) * 2011-09-13 2013-03-21 Universite De Montreal Combinaison thérapeutique utilisant la ribavirine en tant qu'inhibiteur d'elf4e
US20140315920A1 (en) * 2013-04-17 2014-10-23 Hedgepath, Llc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
WO2016011328A1 (fr) * 2014-07-17 2016-01-21 Baker Cheryl Traitement du cancer associant un rayonnement, des nanoparticules d'oxyde de cérium et un agent chimiothérapeutique

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005249502A1 (en) * 2004-05-28 2005-12-15 Schering Corporation Particulate-stabilized injectable pharmaceutical compositions of posaconazole
JP2008514726A (ja) * 2004-09-30 2008-05-08 ザ ユニヴァーシティー オヴ シカゴ ヘッジホッグ阻害剤、放射線及び化学療法薬の併用療法
US8293754B2 (en) * 2005-06-14 2012-10-23 Aska Pharmaceutical Co., Ltd. Thienopyrimidine derivatives
JP5435946B2 (ja) * 2005-08-22 2014-03-05 ジョンズ ホプキンス ユニバーシティ 疾患を処置するためのヘッジホッグ経路アンタゴニスト
JP5205034B2 (ja) * 2007-11-06 2013-06-05 ローム株式会社 面発光レーザダイオード
WO2012006584A2 (fr) * 2010-07-08 2012-01-12 Infinity Pharmaceuticals, Inc. Régimes thérapeutiques pour les cancers associés à la voie de signalisation hedgehog

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013037043A1 (fr) * 2011-09-13 2013-03-21 Universite De Montreal Combinaison thérapeutique utilisant la ribavirine en tant qu'inhibiteur d'elf4e
US20140315920A1 (en) * 2013-04-17 2014-10-23 Hedgepath, Llc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
WO2016011328A1 (fr) * 2014-07-17 2016-01-21 Baker Cheryl Traitement du cancer associant un rayonnement, des nanoparticules d'oxyde de cérium et un agent chimiothérapeutique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2018191541A1 *

Also Published As

Publication number Publication date
AU2018253189A1 (en) 2019-12-05
WO2018191541A1 (fr) 2018-10-18
CA3063115A1 (fr) 2018-10-18
EP3609329A1 (fr) 2020-02-19
KR20200059188A (ko) 2020-05-28
CN111093373A (zh) 2020-05-01

Similar Documents

Publication Publication Date Title
EP3891149A4 (fr) Inhibiteurs de ret, compositions pharmaceutiques et utilisations associées
EP3642182A4 (fr) Composés, compositions et procédés de synthèse
EP3436482A4 (fr) Anticorps, compositions pharmaceutiques et procédés
EP3665156A4 (fr) Composés, compositions et procédés
EP3585433A4 (fr) Compositions thérapeutiques et méthodes associées pour la photoimmunothérapie
HK1243999A1 (zh) 新型3-吲哚取代的衍生物、藥物組合物及使用方法
EP3675859A4 (fr) Composés, compositions et méthodes pour le traitement d'une maladie
EP3491026A4 (fr) Anticorps humains, compositions pharmaceutiques et procédés
EP3466943A4 (fr) Composé de diphénylaminopyrimidine et de triazine, composition pharmaceutique et utilisation de celui-ci
EP3585426A4 (fr) Compositionset méthodes de transduction tumorale
EP3891148A4 (fr) Inhibiteurs de ret, compositions pharmaceutiques et utilisations associées
EP3369734A4 (fr) Inhibiteur de kinase et procédé pour sa préparation et utilisation pharmaceutique correspondante
EP3675860A4 (fr) Pyrimidines substituées, compositions pharmaceutiques et méthodes thérapeutiques associées
EP3877381A4 (fr) Benzamides de dérivés de pyrazolyl-amino-pyrimidinyle, compositions et procédés associés
HK1256674A1 (zh) 氘修飾的brigatinib衍生物、含有該化合物的藥物組合物及其用途
EP3347348A4 (fr) Préparation de 3-hydroxy-3,6-diméthylhexahydrobenzofuran-2-one et de dérivés de celle-ci
EP3689857A4 (fr) Composé de griseofulvine et son utilisation pharmaceutique
EP3670511A4 (fr) Composé de tétrahydroprotoberbérine, son procédé de préparation, ses utilisations et composition pharmaceutique
EP3773654A4 (fr) Compositions médicamenteuses polypharmaceutiques et méthodes associées
EP3388433A4 (fr) Dérivé de phthalazine et procédé de préparation, composition pharmaceutique et utilisation associées
EP3638270A4 (fr) Compositions et méthodes pour l'amélioration d'un traitement par hyperthermie
EP3664797A4 (fr) Ligands de nr4a1, compositions pharmaceutiques et procédés d'utilisation associés
EP3551613A4 (fr) Composés et compositions pharmaceutiques pour moduler l'activité sgk, et leurs procédés
EP3284743A4 (fr) Composés d'imidazole hétérocycliques, compositions pharmaceutiques les contenant, leur procédé de préparation et utilisation
EP3717502A4 (fr) Compositions et procédés de caractérisation du cancer

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191112

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40013994

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20210211

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20210205BHEP

Ipc: A61K 31/475 20060101ALI20210205BHEP

Ipc: A61P 35/00 20060101ALI20210205BHEP

Ipc: A01N 43/48 20060101AFI20210205BHEP

Ipc: A61K 31/496 20060101ALI20210205BHEP

Ipc: A61K 31/337 20060101ALI20210205BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20231101